Pharma BD Deal Intelligence
GSK puts $1.4B on the line in Aiolos acquisition to boost asthma pipeline with Phase II-ready anti-TSLP monoclonal antibody AIO-001
ClinicalTrials.gov NCT06748053 (Tier 4 primary registry record): Phase 2, multicentre, randomized, double-blind, placebo-controlled, dose-finding study of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK acquired Aiolos Bio for $1.0B upfront plus up to $400M in success-based regulatory milestones (announced 2024-01-09, completed 2024-02-15) to add a Phase 2-ready, long-acting anti-TSLP monoclonal antibody, AIO-001 (now GSK5784283; also SHR-1905), to its respiratory franchise. AIO-001's potency and half-life extension support potential dosing as infrequently as every six months for adult asthma, positioning GSK against Amgen/AstraZeneca's Tezspire. The asset entered a Phase 2 dose-finding asthma study (NCT06748053) in February 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Aiolos Bio (this deal) | 2024 | $1.0B | 60 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2024 deals · GSK plc deals · Respiratory deals